Tenders Are Invited For Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V From November 1St, 2025 / January 1St, 2026

Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V From November 1St, 2025 / January 1St, 2026. Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Betaine.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Budesonide + Formoterol (Ihp).,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Cefadroxil In The Dosage Form Tab.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Clonazepam Tab.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Cyproterone.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Dexamethasone In The Dosage Form Amp.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Dexketoprofen In The Dosage Forms Iil And Ilo.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Doxepin With An Effective Strength Of 75 Mg.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Escitalopram In The Dosage Form Tei.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Fluticasone In The Dosage Form Ihp And From An Effective Strength Of 0.25 Mg.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Glatiramer Acetate In The Dosage Form Pen And From An Effective Strength Of 40 Mg/Ml.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Ibuprofen In The Dosage Form Fta And From An Effective Strength Of 400 Mg As An Otc Medicine.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V With The Active Ingredient Ipratropium Bromide.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Isosorbide Mononitrate, The Dosage Forms Ret/Rek And Selected Strengths.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Lercanidipine.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Lopinavir + Ritonavir In The Dosage Form Fta.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Methylphenidate In Selected Strengths And Dosage Forms.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V With The Active Ingredient Metoprolol In The Dosage Form Ret And The Effective Strength 50Mg.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Moxifloxacin In The Dosage Form Atr.,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Octreotide In The Dosage Forms Pls And